- Home
- SKX vs LEGN Comparison
SKX vs LEGN Comparison
Compare SKX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKX
- LEGN
- Stock Information
- Founded
- SKX 1992
- LEGN 2014
- Country
- SKX United States
- LEGN United States
- Employees
- SKX N/A
- LEGN N/A
- Industry
- SKX Shoe Manufacturing
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- SKX Consumer Discretionary
- LEGN Health Care
- Exchange
- SKX Nasdaq
- LEGN Nasdaq
- Market Cap
- SKX 6.9B
- LEGN 7.0B
- IPO Year
- SKX 1999
- LEGN 2020
- Fundamental
- Price
- SKX $62.09
- LEGN $27.78
- Analyst Decision
- SKX Buy
- LEGN Strong Buy
- Analyst Count
- SKX 13
- LEGN 13
- Target Price
- SKX $70.33
- LEGN $75.67
- AVG Volume (30 Days)
- SKX 11.7M
- LEGN 1.5M
- Earning Date
- SKX 04-24-2025
- LEGN 05-13-2025
- Dividend Yield
- SKX N/A
- LEGN N/A
- EPS Growth
- SKX 9.64
- LEGN N/A
- EPS
- SKX 4.16
- LEGN N/A
- Revenue
- SKX $9,129,335,000.00
- LEGN $728,303,000.00
- Revenue This Year
- SKX $7.83
- LEGN $65.96
- Revenue Next Year
- SKX $6.94
- LEGN $52.55
- P/E Ratio
- SKX $14.91
- LEGN N/A
- Revenue Growth
- SKX 10.66
- LEGN 112.46
- 52 Week Low
- SKX $44.50
- LEGN $29.27
- 52 Week High
- SKX $78.85
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- SKX 68.72
- LEGN 29.61
- Support Level
- SKX $61.97
- LEGN $30.25
- Resistance Level
- SKX $61.70
- LEGN $33.30
- Average True Range (ATR)
- SKX 0.61
- LEGN 1.78
- MACD
- SKX 1.04
- LEGN -0.57
- Stochastic Oscillator
- SKX 97.40
- LEGN 5.19
About SKX Skechers U.S.A. Inc.
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.